Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
Divestment of Aspen’s European Thrombosis Business to Mylan and Withdrawal of Cautionary
Details : Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.
Brand Name : Arixtra
Molecule Type : Small molecule
Upfront Cash : $310.4 million
September 08, 2020
Lead Product(s) : Fondaparinux Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Viatris
Deal Size : $757.2 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
